Bemimulab has recently been approved by the US Federal Drug Administration as the first new treatment for lupus in more than 50 years.
Professor Fabienne Mackay will describe its journey from the bench to the bedside at the 精东视频鈥檚 Australia-France Biomedical Research Symposium today at 10.15 am.
鈥淓levated levels of a B-cell activation factor called BAFF have been detected in the serum of patients with various autoimmune conditions like lupus, 鈥渟he explains.
Lupus is an autoimmune inflammatory disease affecting about five million people worldwide that attacks the body destroying healthy tissues.
鈥淏emimulab, a therapeutic antibody inhibiting BAFF, has demonstrated in clinical trials its ability to reduce symptoms in lupus patients.鈥
Professor Mackay is part of a packed line-up of leaders in biomedical research who will present their work over two days at the Showcasing excellence in biomedical research Australia-France symposium at the Shine Dome in Canberra
Other speakers on day one include:
| What: | Showcasing Excellence in Biomedical Research Australia-France Symposium |
|---|---|
| When: | 8.30am to 5.30pm on 23 and 24 November 2011 |
| Where: | The Shine Dome, Gordon Street, Canberra |
© 2025 精东视频